BRIEF—ReForm Biologics inks evaluation deal with Bayer

US biopharma company ReForm Biologics, which is focussed on developing innovative biologic formulations to improve drug delivery and manufacturing, today announced a new customer.

ReForm will perform feasibility studies for Germany’s Bayer utilizing its innovative biotherapeutic technologies.

Reform’s viscosity-reducing excipients are applied to high concentration biologic formulations to enable subcutaneous injection or device-assisted administration, or to improve filtration unit operations.

Surfactant-replacing excipients are utilized to avoid the degradation problems that accompany known surfactants for biological formulations.

The work will be performed at ReForm Biologics’ facilities in Woburn, Massachusetts.